Interest in continued use after participation in a study of over-the-counter progestin-only pills in the United States

Kate Grindlay, Katherine Key, Carmela Zuniga, Alexandra Wollum, Kelly Blanchard, Daniel Grossman

Women’s Health Reports

Abstract 

Objective 

To assess interest in continued use of over-the-counter progestin-only pills among individuals who used them in a trial.

Methods 

From January 2020 to September 2021, we conducted a cross-sectional online survey with individuals who completed participation in a trial evaluating over-the-counter use of norgestrel 0.075 mg tablets in the United States. We calculated descriptive statistics, Pearson's chi-square and Fisher's exact tests, and logistic regression models to assess likelihood of future over-the-counter progestin-only pill use, reasons for interest/noninterest, situations for over-the-counter progestin-only pill use, willingness to pay for an over-the-counter progestin-only pill, likelihood of future preventive health screenings, prior difficulties getting prescription contraception, and background characteristics.

Results 

Among 550 adult and 115 adolescent participants (75% response rate), 83% reported likelihood of future over-the-counter progestin-only pill use. Hispanic/Latinx and Black participants and adults with public insurance, prior pregnancies, and some college reported higher likelihood of future use compared with their counterparts. Among likely users, 90% were interested in long-term use and 79 % ≥ 25 years of age reported they would get future preventive screenings; participants would pay up to $20/month on average. Primary reasons for interest included convenience (81%), ease of access (80%), and saving time (77%) and money (64%). The primary reason for noninterest was bleeding associated with progestin-only pill use (52%).

Conclusion 

There was high interest in continuing to use over-the-counter progestin-only pills among individuals who had used them in a study. These findings highlight the real-world acceptability of taking a progestin-only pill without a prescription, and contribute to evidence supporting over-the-counter access.

Previous
Previous

Over-the-counter oral contraception in the United States: An important opportunity at a time of increased concern about contraceptive access

Next
Next

Pilot label comprehension study for an over-the-counter combined oral contraceptive pill in the United States